Israel-based Nevia formerly known as Gina Life, is a FemTech company dedicated to advancing women's health by detecting early diseases through the analysis of vaginal secretions, driven by Nevia's Machine Learning Platform. The company uses machine learning and data science techniques to identify unique biomarkers. The company aims to make the test available for regular screenings and eventually as a home-use test.
As of May 2024, the company has three programs in development: Nevia 001(for ovarian cancer), Nevia 002(for Endometriosis), and Nevia 003 (Stealth Mode), all aimed at advancing their mission of early disease detection in women's health.
Funding and financials
In August 2023, the company raised USD 3.1 million in a seed funding round led by MindUP Digital Health Incubator to advance clinical trials for its lead ovarian cancer program, which decodes biomarker data from vaginal secretions for early detection.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.